

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081801 A2

(51) International Patent Classification:

A61K 31/4439 (2006.01) A61K 45/06 (2006.01)
A61K 31/17 (2006.01) A61P 7/06 (2006.01)
A61K 31/4196 (2006.01)

(21) International Application Number:

PCT/US2022/079277

(22) International Filing Date:

04 November 2022 (04.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/276,498 05 November 2021 (05.11.2021) US
63/286,461 06 December 2021 (06.12.2021) US
63/291,191 17 December 2021 (17.12.2021) US

(71) Applicant: **GLOBAL BLOOD THERAPEUTICS, INC.**
[US/US]; 181 Oyster Point Boulevard, South San Francisco,
California 94080 (US).

(72) Inventor: **WASHINGTON, Carla B.**; c/o Global Blood
Therapeutics, Inc., 181 Oyster Point Boulevard, South San
Francisco, California 94080 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; PFIZER INC., 100
Route 206 North, Mail Stop: SOM-PPK4-LLA403, Pea-
pack, NJ 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF ADMINISTERING VOXELOTOR




FIG. 1

(57) Abstract: Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients, wherein the patient is about 4 years old to less than about 12 years old. Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients also having severe hepatic impairment. Also provided herein are methods for administering voxelotor and avoiding or lessening adverse drug interactions with a CYP3A4 inducer or inhibitor. Also provided herein are methods for avoiding interactions with voxelotor, a moderate CYP3A4 inhibitor.

[Continued on next page]

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*